Page last updated: 2024-10-24

positive regulation of toll-like receptor 9 signaling pathway

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate, or extent of toll-like receptor 9 signaling pathway. [GOC:add, PMID:16551253, PMID:17328678]

Positive regulation of toll-like receptor 9 (TLR9) signaling pathway is a crucial process in the innate immune system, involving a cascade of molecular events that lead to the activation of immune cells and the initiation of an inflammatory response. TLR9, a pattern recognition receptor expressed primarily in endosomes of immune cells like dendritic cells, B cells, and macrophages, plays a key role in recognizing and responding to pathogen-associated molecular patterns (PAMPs) like unmethylated CpG DNA, commonly found in bacterial and viral DNA. Upon encountering CpG DNA within endosomes, TLR9 undergoes conformational changes and dimerizes, leading to the recruitment of adaptor proteins, primarily MyD88. This interaction triggers a signaling cascade involving the activation of downstream kinases, including IRAK1 and IRAK4, which subsequently activate TRAF6. TRAF6 then orchestrates the formation of a signaling complex that activates TAK1 kinase. TAK1, in turn, activates two major downstream pathways: the NF-κB pathway and the MAPK pathway. The NF-κB pathway leads to the production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-12, while the MAPK pathway promotes the production of type I interferons (IFNs), which are critical for antiviral responses. These signaling events ultimately culminate in the activation of immune cells, including dendritic cells, macrophages, and B cells, leading to the development of adaptive immune responses. The positive regulation of TLR9 signaling pathway is tightly controlled by a complex network of regulatory mechanisms to ensure an appropriate immune response and prevent excessive inflammation. These regulatory mechanisms involve both positive and negative feedback loops, ensuring that TLR9 signaling is activated only when necessary and is appropriately terminated once the threat is neutralized. In addition to these core events, other regulatory processes contribute to the positive regulation of TLR9 signaling. These include the involvement of co-receptors like CD14, which enhance TLR9 activation, and the modulation of TLR9 expression by factors like IFN-γ and TNF-α. Furthermore, the localization and trafficking of TLR9 within the cell play a crucial role in its signaling capacity. Overall, the positive regulation of TLR9 signaling pathway is a dynamic and complex process that is essential for the host to mount an effective immune response against invading pathogens.'
"

Proteins (3)

ProteinDefinitionTaxonomy
Toll-like receptor 9A Toll-like receptor 9 that is encoded in the genome of human. []Homo sapiens (human)
Reticulon-4A reticulon-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NQC3]Homo sapiens (human)
High mobility group protein B1A high mobility group protein B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09429]Homo sapiens (human)

Compounds (6)

CompoundDefinitionClassesRoles
salicylic acidScalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
diflunisaldiflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.

Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
monohydroxybenzoic acid;
organofluorine compound
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
hydroxychloroquinehydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
glycyrrhizic acidglycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin
EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
methotrexatedicarboxylic acid;
monocarboxylic acid amide;
pteridines
abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
ARS-1620ARS-1620 : A qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals.

ARS-1620: covalent S-IIP G12C inhibitor for targeting of KRAS G12C mutant tumors
quinazolinesantineoplastic agent;
antiviral agent;
inhibitor